Pamisell Q3 Operating Profit 1.3 Billion KRW... Up 150.4% YoY

Pharmicell announced on the 6th that it recorded sales of 14.6 billion KRW and an operating profit of 1.3 billion KRW in the third quarter. Compared to the same period last year, sales increased by 19.9% and operating profit rose by 150.4%. The cumulative sales for the third quarter reached 43.4 billion KRW, operating profit was 1.5 billion KRW, and net profit was 2.2 billion KRW.

The low dielectric constant materials, which led the sales increase in the third quarter, amounted to 6.4 billion KRW, a 209.2% increase from 2.1 billion KRW in the same period last year. This year, sales of these materials reached 15.3 billion KRW through the third quarter, establishing them as a major product item. Copper clad laminates (CCL) using low dielectric constant materials are utilized in artificial intelligence (AI) accelerators. As global companies are building data centers, demand for low dielectric constant materials is increasing. Sales are expected to continue growing in the fourth quarter of this year.

A Pharmicell representative stated, "Last month, at the international pharmaceutical and bio exhibition CPHI, we held meetings with global companies from the US, Europe, India, Japan, and China," adding, "We are currently sending samples of newly developed active pharmaceutical ingredients." They further added, "We will expand our global supply chain by diversifying our client base."

This content was produced with the assistance of AI translation services.